Ionis Pharmaceuticals (IONS)
(Delayed Data from NSDQ)
$47.68 USD
-2.22 (-4.45%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $47.69 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$47.68 USD
-2.22 (-4.45%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $47.69 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Zacks News
Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate
by Zacks Equity Research
A low key week for the biotech sector with focus on regular pipeline updates.
Biogen (BIIB) In-Licenses ALS Candidate BIIB067 From Ionis
by Zacks Equity Research
Biogen (BIIB) obtains a license to develop and commercialize BIIB067 from Ionis Pharmaceuticals. The candidate is being developed for treatment of ALS with SOD1 mutations.
Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 76.92% and 9.82%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: GILD Gets EC Nod for Yescarta, AMGN Submits Kyprolis sNDA
by Zacks Equity Research
Regulatory and pipeline updates comprise some of the key developments in the biotech sector this week. These include Gilead's Yescarta approval in Europe.
Pfizer's Tafamidis Fails to Impress in Cardiomyopathy Study
by Zacks Equity Research
Pfizer's (PFE) tafamidis significantly reduces rate of mortality and cardiovascular-related hospitalization in patients with transthyretin amyloid cardiomyopathy. However, it fails to impress investors. Stock dips.
Ionis Pharmaceuticals (IONS) Looks Good: Stock Adds 7.8% in Session
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of -150.00% and -8.17%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Ionis (IONS) Posts Wider than Expected Loss in Q2, Sales Miss
by Zacks Equity Research
Ionis posts wider than expected loss and sales miss estimates in the second quarter of 2018.
Is a Beat in Store for Ionis (IONS) This Earnings Season?
by Zacks Equity Research
On Ionis' (IONS) second-quarter 2018 conference call, investor focus will remain on the company's progress with the pipeline candidates as well as royalty revenues earned from Spinraza.
Biogen (BIIB) Q2 Earnings & Sales Beat Estimates, Shares Up
by Zacks Equity Research
Biogen (BIIB) beats estimates on both counts in the second quarter. The company's multiple sclerosis drugs' sales up sequentially amid competition.
Biotech Stock Roundup: AMGN Resubmits Evenity BLA, Advaxis Soars, Regulatory Updates
by Zacks Equity Research
It has been a pretty ho-hum week for the biotech sector with a few regulatory updates. Amgen resubmits BLA for osteoporosis drug and Advaxis surges on positive news from FDA.
Bristol-Myers' Combo Drugs Get FDA Nod for Colorectal Cancer
by Zacks Equity Research
Bristol-Myers' (BMY) Opdivo in combination with its Yervoy received the FDA approval to treat patients with metastatic colorectal cancer (mCRC) that has progressed following treatment with fluoropyrimidine, oxaliplatin and irinotecan.
Summit Therapeutics (SMMT) Catches Eye: Stock Jumps 8.8%
by Zacks Equity Research
Summit Therapeutics (SMMT) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Regulus Stock Plunges on Cash Concerns Despite Restructuring
by Zacks Equity Research
Regulus Therapeutics (RGLS) announces strategic and restructuring plans to extend cash runway. However, investors remain skeptical.
Pfizer's Tafamadis Gets Breakthrough Therapy Designation
by Zacks Equity Research
Pfizer's (PFE) rare disease candidate, tafamidis, gets Breakthrough Therapy designation in the United States for the treatment of transthyretin cardiomyopathy.
Ionis (IONS) Beats Earnings & Misses Revenues in Q1
by Zacks Equity Research
Ionis Pharmaceutical (IONS) reported positive quarter with earnings beating estimates while revenues missing the same.
What's in the Cards for Ionis (IONS) This Earnings Season?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) earns $30 million in license payments from AstraZeneca. Spinraza witnesses strong first quarter as announced by Biogen in its earnings release.
Ionis Pharmaceuticals (IONS) in Focus: Stock Moves 5.8% Higher
by Zacks Equity Research
Shares of Ionis Pharmaceuticals (IONS) rose 5.8% on Friday.
Ionis (IONS) Clinches Licensing Agreement with AstraZeneca
by Zacks Equity Research
Ionis (IONS) inks a licensing deal with AstraZeneca per which the former will license IONIS-AZ6-2.5-LRx to AstraZeneca for the treatment of NASH.
Alnylam Falls on Pfizer's Rare Disease Drug Success
by Zacks Equity Research
Shares of Alnylam (ALNY) fall by more than 8% after Pfizer reports top-line results from the phase III study of tafamidis.
Pfizer's Rare Disease Candidate Meets Endpoint in Phase III
by Zacks Equity Research
Pfizer's (PFE) pipeline candidate tafamidis, developed for the treatment of transthyretin cardiomyopathy (TTR-CM), meets the main goal in a late-stage study.
Biogen to Buy Mid-Stage Neuropsychiatry Asset From Pfizer
by Zacks Equity Research
Biogen (BIIB) agrees to pay $75 million upfront to buy mid-stage candidate from Pfizer, which is being developed for cognitive impairment associated with schizophrenia (CIAS).
Ionis (IONS) Beats Both Earnings & Revenues in Q4
by Zacks Equity Research
Ionis Pharmaceutical (IONS) reported positive quarter with earnings and revenues beating estimates.
What's in the Cards for Ionis (IONS) This Earnings Season?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) earns $70 million in milestone and license payments from several drug companies. Spinraza witnesses strong fourth quarter as announced by Biogen in its earnings release.
Ionis Out-Licenses Second Candidate to AstraZeneca, Earns $30M
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) out-licenses Generation 2.5 antisense drug to AstraZeneca under a strategic collaboration agreement.